ReviewNature medicine2018
Is earlier better for melanoma checkpoint blockade?
Review in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma.Journal of translational medicine · 2025Article
- Review
- Opportunities for Discovery Using Neoadjuvant Immune Checkpoint Blockade in Melanoma.International journal of molecular sciences · 2025Review
- Efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a prospective cohort study with propensity-score matching.Frontiers in immunology · 2025Article
- Neoadjuvant systemic therapy for hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?Annals of surgical oncology · 2023Article
- Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.Cancers · 2023Review
- Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice.Annals of surgery · 2023Article
- The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.Chronic diseases and translational medicine · 2022Review
- Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.Human vaccines & immunotherapeutics · 2022Review
- Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.Cells · 2022Review
- Neoadjuvant immunotherapy for resectable esophageal cancer: A review.Frontiers in immunology · 2022Review
- Prognostic significance of OX40Oncoimmunology · 2021Article
- Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.Nature reviews. Clinical oncology · 2020Review
- Article
- Review
- Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer.Frontiers in oncology · 2020Review
- Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.Journal of immunology research · 2020Review
- Article
- New paradigm for stage III melanoma: from surgery to adjuvant treatment.Journal of translational medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A neoadjuvant approach relying on the administration of combined anti-CTLA-4-anti-PD-1 treatment before lymph node surgery is evaluated in two phase 1 trials. Encouraging clinical, pathological and immunological responses to neoadjuvant therapy were observed, suggesting that this concept warrants further exploration; however, any future approach must address the unacceptably high toxicity of the regimens evaluated in these trials.
Indexed as
Identifiers
30401867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.